Peptide CIGB‐552 has a synergistic effect on CFTR‐F508del when combined with elexacaftor/tezacaftor/ivacaftor triple therapy for cystic fibrosis
COMMD1 expression was necessary for CIGB-552 to affect CFTR function positively. Its synergy with the triple therapy offers a promising strategy for improving CF treatment.
Authors
- Bruno Costes
- Aurélie Guguin
- Maribel Guerra Vallespí (ORCID: https://orcid.org/0000-0002-4043-2364)
- Benjamin Simonneau (ORCID: https://orcid.org/0009-0005-3083-0325)
- Pascale Fanen (ORCID: https://orcid.org/0000-0002-3273-5349)
- Christelle Coraux (ORCID: https://orcid.org/0000-0001-5345-5074)
- Bénédicte Duriez (ORCID: https://orcid.org/0000-0002-0798-8969)
- Frédéric Becq (ORCID: https://orcid.org/0000-0003-3915-0973)
- Sandra Mirval
- Fanny Degrugillier (ORCID: https://orcid.org/0000-0001-7404-1022)
- Abdel Aissat
- Stéphanie Simon
Institutions
- Inserm (FR)
- Université Paris-Est Créteil (FR)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Université de Poitiers (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpitaux Universitaires Henri-Mondor (FR)
- Centro de Ingeniería Genética y Biotecnología (CU)
- Institut Mondor de Recherche Biomédicale (FR)
- Pathologies Pulmonaires et Plasticité Cellulaire
- Université de Reims Champagne-Ardenne (FR)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2025-08-14
- DOI
- https://doi.org/10.1111/bph.70169
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Institut National de la Santé et de la Recherche Médicale
- Association Vaincre la Mucoviscidose
- Chancellerie des Universités de Paris